0,1,2,3,4,5,6,7
Table 6.3.10:  Treatment-related toxicity and BCR-free survival in selected SABR studies,,,,,,,
Study,Study design,"n and 
RT-type","Median 
FU (mo)","Fractionation
(SD/TD)",ADT,"Treatment 
toxicity","BCR-free 
survival"
"Bergamin, 
et al. 2020 
[1096]","single-centre 
prospective","25 
LINAC
based",25,"SD 6-6.2
TD 36-38 Gy",0/25,"2 yr. late 
G1 GI 8% 
G2 GU 4%",2 yr. 80%
"Fuller, et al. 
2020 [1095]","single-centre 
retrospective","50
Cyber Knife",44,"SD 6.8 Gy
TD 34 Gy",7/50,"5 yr: 8% late 
G3+ GU",5 yr. 60%
"Pasquier, 
et al. 2020 
[1094]","multi-centre 
retrospective","100 
Cyber Knife",30,"SD 6 Gy
TD 36 Gy","34/100
median 
12 mo.","3 yr. grade 2+ 
GU 20.8%
GI 1%",3 yr. 55%
